



Treating Cancer

# Oncolytic Viral Vaccine

[view website](#)

## Oncolytic Viral Vaccine Toxicology at CBI

Oncolytic viral vaccines represents a novel and exciting approach to the treatment of cancer.

In 2015, the U.S. Food and Drug Administration approved the first oncolytic virus immunotherapy for the treatment of cancer - T-VEC for melanoma. There are now a number of exciting new products in development. CBI has conducted a number of toxicology programs with oncolytic viral vaccines for our clients.

**All CBI STUDIES SUCCESSFUL!**

**CBI specializes in customizing, designing and implementing GLP toxicology studies for regulatory submissions as well as research and nonGLP studies with oncolytic vaccine products:**

- Immune-incompetent or competent mice, both tumor bearing and non-tumor bearing
- Unique and specialized assessments
- Murine cardiac troponins
- Immunohistochemistry
- Cytokines and mediators
- qPCR, Print and ADA bioassays
- Customized and special assays

- CUSTOM UPON REQUEST -

**NEED TO CONDUCT A STUDY?**

[Click here and check out our website. www.compbio.com](http://www.compbio.com)



786 Lucerne Drive . Sunnyvale, CA 94085 . Telephone 408-738-9260